AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06762951 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pilates mat exercices
Description: Pilates mat exercise which consists of (single leg stretch + Pelvic press + Swimming + Opposite arm and leg reach + Side to side), 3 sets of 10 repetitions.
Study NCT06762951 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Segmental control exercises
Description: Segmental control exercise which consists of (Segmental control over primary stabilizers, Exercises in closed chain, and Exercises in open chain)
Study NCT06762951 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Traditional physical therapy
Description: Traditional physical therapy eg. (Back, hamstring, calf and hip flexors stretches, Abdominal curl-up exercise in supine, Back extensors exercise in prone, and Hip extensors exercises in prone along with ultrasound and Transcutaneous electrical nerve stimulation (TENS)
Study NCT06762951 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional physical therapy
Description: Traditional physical therapy eg. (Back, hamstring, calf and hip flexors stretches, Abdominal curl-up exercise in supine, Back extensors exercise in prone, and Hip extensors exercises in prone along with ultrasound and Transcutaneous electrical nerve stimulation (TENS)
Study NCT06762847 — intervention group
Intervention type: DEVICE
Intervention: Use of Conventional Silicone Prosthetic Liner
Description: At this stage participant who will be fitted with a standard silicone liner typically used for transtibial prosthetics. Over a set duration, we will assess the liner's performance, particularly in terms of durability, comfort, skin health, and fit stability. Acting as the control group, this cohort will provide essential baseline data for comparison with the innovative prosthetic liner.
Study NCT06764238 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Blinatumomab (Group A)
Description: For Group A I/HR-ALL patients after induction remission phase, continuous 28 days' blinatumomab followed by 3 cycles of high-dose methotrexate (HDMTX) will be applied, subsequently followed by interim continuation, late intensification, and maintenance therapy
Study NCT06764238 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax (nonRand Group)
Description: For I/HR patients non eligible for blinatumomab randomization, venetoclax+ mini-hyperCVD will be applied after PVDL induction, subsequently followed by CAT as intensification, interim continuation, late intensification, and maintenance therapy
Study NCT06764238 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Blinatumomab (Group B)
Description: For Group B I/HR-ALL patients after induction remission phase: a two 14-day cycles of blinatumomab, alternating with three cycles of HDMTX will be applied, subsequently followed interim continuation, late intensification, and maintenance therapy
Study NCT06762730 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zoledronic Acid 5 mg/Bag 100 ml Inj
Description: Zolendric acid will be provided to HIV naïve patients with documented osteopnia
Study NCT06762925 — intervention group
Intervention type: OTHER
Intervention: No Interventions
Description: No Interventions
Study NCT06764186 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: 2 intramuscular injections of 500 mg given on Day 1 of Weeks 1 and 3 of cycle 1, and then on Day 1, Week 1 of each cycle thereafter.
Study NCT06764186 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capivasertib
Description: 400 mg (2 oral tablets) BD given on an intermittent weekly dosing schedule. Dosed on Days 1 to 4 in each week of a 28-day treatment cycle
Study NCT06762873 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Drug Induced Sleep Endoscopy with PNS
Description: Enrolled subjects will complete an overnight PSG and then undergo a DISE procedure with a 30-minute research period.
Study NCT06763874 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EMG-based FES device
Description: One session of one hour to execute task-oriented exercises with the upper limb while wearing the EMG-based FES device. Submission of questionnaires related to usability, acceptance and satisfaction of the device.
Study NCT06763419 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: External low level laser therapy
Description: Patients received 8 sessions of external diode laser (635 nm).
Study NCT06763419 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Internal low level laser therapy
Description: Patients received 8 diode laser (635 nm) sessions applied internally
Study NCT06506422 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin 10 MG
Description: 10mg Empagliflozin daily for 12 weeks
Study NCT06506422 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 10mg Placebo daily for 12 weeks
Study NCT06320626 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Emicizumab - PK-guided dose reduction
Description: PK-guided dose reduction emicizumab targeted at a Ctrough of 30μg/mL.
Study NCT06320626 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Emicizumab - Dosis continuation group
Description: Continue on their current dose regimen
Study NCT06320626 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Emicizumab - Dose adjustment group
Description: Adjusted in dosing regimen according to local protocol
Study NCT05395988 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Digital hand washing instructions
Description: Tablet displaying animated hand washing instructions
Study NCT05395988 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Digital hand washing reward
Description: Tablet displaying animated hand washing instructions and animated animals as reward
Study NCT04829721 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational Intervention with video
Description: Women randomized to an educational video workshop group.
Study NCT05848921 — intervention group
Intervention type: DEVICE
Intervention: magnetic resonance image
Description: Imaging data were collected in a strong magnetic field
Study NCT05848921 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Neuropsychological scale
Description: Multi dimensional neuropsychological test
Study NCT05599802 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 variant mRNA vaccine low dose
Description: 50μg/dose
Study NCT05599802 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 variant mRNA vaccine high dose
Description: 100μg/dose
Study NCT04945421 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab
Description: (IBI310 3 mg/kg IV d1, Q3W combined with sintilimab 100 mg IV d1, Q3W) or( IBI310 1 mg/kg IV d1, Q3W combined with sintilimab 200 mg IV d1, Q3W) for up to 4 cycles, and then sintilimab 200 mg IV d1, Q3W until progressive disease, intolerable toxicity, start of a new antitumor treatment, withdrawal of informed consent, loss to follow-up, death or other situations requiring termination of treatment specified in the protocol, whichever occurs first.
Study NCT04945421 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI310
Description: (IBI310 3 mg/kg IV d1, Q3W combined with sintilimab 100 mg IV d1, Q3W) or( IBI310 1 mg/kg IV d1, Q3W combined with sintilimab 200 mg IV d1, Q3W) for up to 4 cycles, and then sintilimab 200 mg IV d1, Q3W until progressive disease, intolerable toxicity, start of a new antitumor treatment, withdrawal of informed consent, loss to follow-up, death or other situations requiring termination of treatment specified in the protocol, whichever occurs first.
Study NCT05809661 — intervention group
Intervention type: BEHAVIORAL
Intervention: implementation of the nurse navigation program
Description: Adult patients with intestinal stoma were contacted continuously for 6 months.
Study NCT04607655 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GB1211
Description: GB1211 is a galectin-3 inhibitor an orally available small molecule anti-fibrotic. It is administered orally twice a day.
Study NCT04607655 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo is administered as inhalation once a day
Study NCT05753865 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SYHX2011
Description: IV infusion, 260 mg/m\^2
Study NCT05753865 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel for injection (albumin-bound)
Description: IV infusion, 260 mg/m\^2
Study NCT04532723 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ExoAtlet II
Description: ExoAtlet II is the second version of an exoskeleton that ExoAtlet has manufactured
Study NCT04896333 — intervention group
Intervention type: OTHER
Intervention: Interaction and exposure with the Robot EBO
Description: The participants will interact with the Robot EBO. The robot will be control by an operator that will conduct a dialogue. The dialogue will include questions related to the social, leisure, activities of daily living and informative areas.
Study NCT04728308 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacain
Description: Before closing the skin incision,Infiltration of 20ml of 0.5% bupivacaine around incision site will be done in the patients of experimental group and 20 ml of distill water will be infiltrated in the pateints of the placebo group
Study NCT04728308 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Bupivacain
Description: Before closing the skin incision,Infiltration of 20ml of 0.5% bupivacaine around incision site will be done in the patients of experimental group and 20 ml of distill water will be infiltrated in the pateints of the placebo group
Study NCT05377281 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peripheral Nerve Tissue Implantation
Description: At the time participants are receiving the standard of care deep brain stimulation (DBS) surgery, a standard incision on the lateral aspect near the ankle is made, the sural nerve is identified, an about 3 cm biopsy of the sural nerve is obtained and the incision is closed. From the biopsied section, the epinerium is removed, fascicles are cut, and (\~5 pieces per side; \~ 5mm length x 1.5 mm diameter: approximately 10 cubic millimeters) implanted bilaterally into the substantia nigra.
Study NCT05698134 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: ROTEM
Description: ROTEM is a commercially available whole blood Viscoelastic-Haemostatic Assay(VHA) point-of-care, global and dynamic haemostasis assessment tests that measures the viscoelastic changes occurring during the haemostatic process. They provide real-time, comprehensive reflection of the interaction between plasma, blood cells and platelets. It display hypo or hyper-coagulable features in patients with cirrhosis. It is widely used prior to cardiac, obstetric, trauma and liver transplant surgery to assess and correct for coagulation defects.
Study NCT05698134 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care
Description: Standard of care
Study NCT05709990 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Solifenacin Succinate 5 MG Oral Tablet [Vesicare]
Description: These patients will receive solifenacin 5-10 MG daily (combined with standard urotherapy) for 8 weeks.
Study NCT05709990 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Description: These patients will receive high dose vitamin D supplementation (more than 2000IU daily) (combined with standard urotherapy) for 8 weeks.
Study NCT05709990 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard urotherapy
Description: These patients will receive standard urotherapyfor 8 weeks.
Study NCT06426017 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High Protein Low Calorie Dietary Intervention
Description: High Protein Diet: Diet consisting of 40-60% total energy from proteins, \<20% total energy from carbohydrates and \<30% total energy from fats.
Study NCT06248398 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery with RobOtol®
Description: Patient having cochlear implantation surgery with RobOtol®.
Study NCT06248398 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Conventional manual surgery
Description: Patient having conventional manual cochlear implantation surgery
Study NCT05305209 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control Group
Description: The patients will receive 12 minutes of intravaginal application and 4 minutes of extracavitary application, twice a week for 6 weeks. The difference compared to the intervention of group 1 is that the device will be off and therefore will not emit energy.
Study NCT05838001 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Wire-guided localization and marker clip localization
Description: Positioning guide wire and marker clip in the center of the breast lesion
Study NCT05838001 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: marker clip localization
Description: Positioning marker clip in the center of the breast lesion
Study NCT05130125 — intervention group
Intervention type: DRUG
Intervention: rFSH
Description: rFSH or HP-hMG or rFSH and HP-hMG
Study NCT04844177 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: conditioning with TLI
Description: Total lymphoid irradiation 4 Gy (days -7, -6) in combination with:~* Fludarabine 150 mg/m2 (days-6, -5, -4, -3, -2)~* Cyclophosphamide 120 mg/kg (days -5, -4, -3)~* Thymoglogulin (Genzyme) 5 mg/kg (days -5, -4)~* Melphalan 180 mg/m2 (day -2)~* Rituximab 100 mg/m2 (day -1)~* Hematopoietic stem cell graft infusion after TCRab/CD19 depletion - day 0
Study NCT05786729 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic Exercise (AER)
Description: Aerobic exercise will be performed by utilizing aerobic exercise equipment 3 times per week.
Study NCT04936971 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Switch from Mycophenolate Mofetil to Everolimus manteinance treatment in Active Comparator Arm
Description: Switch from Mycophenolate Mofetil in Active comparator Arm if assymptomatic Cytomegalovirus viremia >1000-\<5000 copies/mL observed
Study NCT04936971 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: no intervention
Description: Manteinance of assigned Arm treatment even if assymptomatic Cytomegalovirus viremia >1000-\<5000 copies/mL observed
Study NCT05786729 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Rehabilitation
Description: Rehabilitative program is focused on completion of activities of daily living, initiation, appropriate behavior and community integration for five days per week at the Centre for Neuro Skills.
Study NCT05842655 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: The wear of screw-retained implant-supported metal-ceramic dental prostheses and natural tooth
Description: A novel digital technique to analyze the wear of screw-retained implant-supported metal-ceramic dental prostheses and natural tooth as antagonist
Study NCT03608280 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bone autograft
Description: The principle of this surgery is based on the removal of a portion of the outer bone layer from the vault of the skull in order to have a flat and solid bone element (cortical bone), which can be carved freehand to better replace the defective bone wall.
Study NCT03608280 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Orbital reconstruction by 3D-printed porous titanium implant
Description: From data of a patient's CT-scan, it is possible to perform a mirroring. The unaffected orbit is mirrored onto the affected orbit, via a virtual treatment planning, in order to rely on facial symmetry to virtually restore healthy anatomy. From this simulation, the implant is 3D-printed by Selective Laser Melted (SLM) technique using titanium powder. This technique enabling the creation of custom-made implants is called computer-aided design and computer-aided manufacturing (CAD-CAM).~After sterilization, the implant is ready to be placed during a surgical procedure.
Study NCT04963205 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Adjustable bed backrest
Description: The adjustable bed backrest facilitates for the individual high lying with a fowler (90 degrees raised head and trunk) and/or semi fowler position (30-45 degrees raised head and trunk) which enables patient's lung expansion. The diaphragm is pulled downwards by the gravity allowing for lung expansion and improved ventilation. In addition, the upper airways are stretched in order to prevent upper airway narrowing during sleep (flow limitation, snoring, obstructive sleep apnea). The position relaxes the tension of the abdominal muscles, allowing for improved breathing. Patients can define their own most comfortable position during the night. Elevated body position over 30 degrees from supine position is a requirement for the intervention group. No sleeping time restrictions will be applied. One week washout period between the interventions will be used.
Study NCT04963205 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard bed
Description: Sleeping in a standard bed, in a position below 30 degrees from supine position. No sleeping time restrictions will be applied. One week washout period between the interventions will be used.
Study NCT05703984 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GC2129A(Period 1)
Description: Linagliptin and Metformin Hydrochloride Tablet
Study NCT05703984 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linaglptin 5mg and Metformin Hydrocholoride 1000mg(Period 1)
Description: Linagliptin 5mg/tab and Metformin Hydrochloride 1000mg/tab (2 tablets)
Study NCT05703984 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GC2129A(Period 2)
Description: Linagliptin and Metformin Hydrochloride Tablet
Study NCT05703984 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Linaglptin 5mg and Metformin Hydrochloride 1000mg(Period 2)
Description: Linagliptin 5mg/tab and Metformin Hydrochloride 1000mg/tab (2 tablets)
Study NCT06246448 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Robotic-assisted radical cholecystectomy
Description: Procedure will be performed robotic-assisted
Study NCT06246448 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open radical cholecystectomy
Description: Procedure will be open
Study NCT05865613 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pulsed electromagnetic field
Description: Participants were randomized into either the PEMF group or sham treatment group by a computer-generated random number. The participants were treated using PEMF (20 G ,7H for 10min) and sham treatment. treatment was delivered for one month.
Study NCT05865613 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Pulsed electromagnetic field
Description: Participants were randomized into either the PEMF group or sham treatment group by a computer-generated random number. The participants were treated using PEMF (20 G ,7H for 10min) and sham treatment. treatment was delivered for one month.
Study NCT06100315 — intervention group
Intervention type: DRUG
Intervention: Nalbuphine
Description: bupivacaine 0.125% of 0.2 ml/kg and 0.1 mg/kg nalbuphine
Study NCT06474897 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ozone therapy
Description: Ozone therapy will be practiced to study group. Inject 10 ml of ozone gas (O2-O3) at a concentration of 10 µg/ml 3 times at one week intervals. All injections will be performed by the same experienced specialist doctor.
Study NCT06474897 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mulligan Mobilization
Description: Mulligan mobilization will be practiced to control group. Mobilizations will be performed once a week for 3 consecutive weeks. The first one is a seated position with the patient's arm in approximately 90° abduction. The patient will be asked to abduct the arm and at the same time the physiotherapist will perform posterio/lateral gliding of the shoulder head with the left hand.
Study NCT06409221 — intervention group
Intervention type: OTHER
Intervention: Non-interventional study, Observational only
Description: Observational study only, there are no planned interventions.
Study NCT06222216 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chilled Needle
Description: Before subcutaneous injection, 26G sterile disposable needles will be kept in the refrigerated compartment of the refrigerator for at least 24 hours. Immediately before SC injection, the needle will be removed from the refrigerator, placed in the ice box and placed next to the patient's bed. The needle temperature will be kept at 0-2 degrees Celsius in the ice box and controlled using an LCD digital thermometer. If Enoxaparin Sodium is in the ready injector, the drug in the injector will be drawn into the injector suitable for 1 cc SC injection application without loss of dose. The needle of the prepared syringe will be replaced with a cooled needle. Afterwards, the injection will be made in the designated area (outer side of the upper arm) in accordance with the SC injection procedure steps. After the injection, the patient's pain assessment will be made and marked on the ILC, and ecchymosis assessment will be made after 24, 48 and 72 hours.
Study NCT06222216 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control Group
Description: SC injection will be administered to the control group in accordance with the clinical routine. No different action will be applied. The injection will be made in accordance with the SC injection protocol with a needle at room temperature, without applying any tools or procedures. After the injection, the patient's pain will be evaluated and marked on the VAS, and ecchymosis will be evaluated after 24, 48 and 72 hours.